Clinical Trials Sponsored by Incyte Corporation

Total 6533 results

Incyte Corporation

No longer available

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

COVID-19
Incyte Corporation

Terminated

Study of INCB053914 in Subjects With Advanced Malignancies

Solid Tumors

United States
Incyte Corporation

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Lymphoma

Spain, Hungary, United States, Denmark, Italy, Czechia
Incyte Corporation

Terminated

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

MPN (Myeloproliferative Neoplasms)

United States
Incyte Corporation

Completed

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Stomach Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastroesophageal Junction Cancer | Urothelial... and other conditions

United States
Incyte Corporation

Completed

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

MPN (Myeloproliferative Neoplasms)

United States, Puerto Rico
Incyte Corporation

Terminated

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

Alopecia Areata

United States
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Incyte Corporation

Terminated

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Sickle Cell Disease

United States
Incyte Corporation

Terminated

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Solid Tumors

United States
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Incyte Corporation

Terminated

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Pancreatic Cancer

United States, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Korea, Republic of, Canada, New Zealand, Australia, Thailand
Incyte Corporation

Terminated

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Breast Cancer

United States, France, United Kingdom, Spain, Italy, Portugal
Incyte Corporation

Terminated

A Study of Ruxolitinib in Pancreatic Cancer Patients

Pancreatic Cancer

United States, France, Colombia, Israel, Portugal, Netherlands, Chile, Puerto Rico, Sweden, Austria, Denmark, Mexico, Ireland, Switzerland
Incyte Corporation

Completed

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Multiple Myeloma

United States
Incyte Corporation

Terminated

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Prostate Cancer

United States
Incyte Corporation

Completed

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Solid Tumors and Hematologic Malignancy

United States
Incyte Corporation

Terminated

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Hodgkin's Lymphoma | Solid Tumor | Metastatic Cancer | Advanced Cancer | NHL (Non-Hodgkin Lymphoma) | UC (Ureter and Urethera)

United States
Incyte Corporation

Terminated

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin's Lymphoma
Incyte Corporation

Completed

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Polycythemia Vera

United States, Belgium, Germany, Spain, Italy, United Kingdom, Ireland
Incyte Corporation

Terminated

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

Breast Cancer

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Healthy Participants

United States
Incyte Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation

Recruiting

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Healthy Participants

United Kingdom
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (TRuE-AD4)

Atopic Dermatitis

Germany, Poland, United States, Spain, United Kingdom, Italy, Belgium, Canada, Netherlands, Australia, Bulgaria, France, Switzerland, Hungary, Korea, Republic of
Incyte Corporation

Recruiting

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Prurigo Nodularis

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
Incyte Corporation

Recruiting

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NonSegmental Vitiligo

Japan, Spain, United States, Poland, Canada, Belgium, Germany, Netherlands, France, Mexico
Incyte Corporation

Recruiting

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United Kingdom, Italy, France, Belgium, Hungary
Incyte Corporation

Recruiting

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Angioedema | Urticaria | Chronic Idiopathic Urticaria | Pruritis | Chronic Spontaneous Urticaria | Hives

United States, Germany, Poland
Incyte Corporation

Recruiting

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Melanoma | Hepatocellular Carcinoma (HCC) | Renal Cell Carcinoma (RCC) | Colorectal Carcinoma (CRC) | Microsatellite Instability - High (MSI-H) | Mismatch Repair Deficient (dMMR)

United States, Brazil, Canada, Australia, Slovakia, Norway, Mexico
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Moderate to Severe Asthma

Korea, Republic of, United States, Spain, Poland, Japan, Canada, Germany, Belgium, Argentina
Incyte Corporation

Recruiting

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Kidney Diseases | Renal Insufficiency

United States, Germany
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)

Hidradenitis Suppurativa (HS)

United States, Canada, Bulgaria, Italy, Spain, Germany, Poland, France, Australia, Denmark, United Kingdom
Incyte Corporation

Recruiting

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

Advanced Malignancies

Spain, United States, France, Italy, Belgium
Incyte Corporation

Recruiting

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) (firmMIND)

Diffuse Large B-Cell Lymphoma | Large B-Cell Lymphoma

Croatia, Serbia, Czechia, Finland, Israel, Romania, Denmark, Hungary, Ireland, Poland, Turkey, Bulgaria, Norway, United Kingdom
Incyte Corporation

Recruiting

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Korea, Republic of, Spain, Italy, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Germany, South Africa, Portugal
Incyte Corporation

Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

B-Cell Malignancies

United States, Spain, Belgium, Japan, Italy, France, United Kingdom, Israel, Turkey, Norway, Korea, Republic of, Czechia, Sweden, Austria, Poland, Hungary, Denmark
Incyte Corporation

Terminated

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Advanced Malignancies

United States, Italy, Denmark, Japan
Incyte Corporation

Terminated

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States
Incyte Corporation

Active, not recruiting

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Melanoma

United States, Australia
Incyte Corporation

Completed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Atopic Dermatitis

United States, Canada
Incyte Corporation

Active, not recruiting

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Metastatic Merkel Cell Carcinoma

United Kingdom, United States, Germany, Canada, Czechia, Italy, France, Spain, Switzerland, Australia, Poland, Hungary
Incyte Corporation

Active, not recruiting

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Hand Eczema

United States, Poland, Canada, Germany
Incyte Corporation

Completed

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Cytokine Release Syndrome

United States
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Incyte Corporation

Active, not recruiting

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma (LIMBER)

Myelodysplastic Syndromes | Multiple Myeloma | Anemia

United States, France, Italy
Incyte Corporation

Active, not recruiting

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Locally Advanced Solid Tumors | Metastatic Solid Tumors

France, Spain, United States, China, United Kingdom, Lithuania, Germany, Ukraine, Finland, Italy, Belgium, Australia, Bulgaria, Latvia, New Zealand, Poland
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Incyte Corporation

Active, not recruiting

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Breast Cancer | Pancreatic Cancer | Lung Cancer | Colorectal Cancer (CRC)

United States

Clinical Trials Sponsored by Incyte Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations